Year: 2020
Type: article
Abstract: Since last December, the outbreak of 2019-nCoV in Wuhan has caused ever-increasing attention and public panic all over the world. Up to February 9, 2020, 40,171 patients had been diagnosed with 2019-nCoV infection, including 6484 (16.14%) severe cases and 908 deaths (2.27%). Compared to SARS and MERS, 2019-nCoV appears to be much more contagious but less lethal, as most patients have mild symptoms and good prognosis 1 , 2 . However, according to the Chinese government’s daily report, 13.2–21.3% of patients with 2019-nCoV infection developed into severe or fatal illness (Fig. S1a ), which is characterized by the rapid development to acute respiratory distress syndrome (ARDS) or septic shock. Along with an increasing number of confirmed cases, the cumulative total of severe patients with 2019-nCoV is growing (Fig. S1b ). Treatment of these critically ill patients is becoming one of the major challenges we are facing.
Authors: Wei Zhou, Yisi Liu, Dongdong Tian, Cheng Wang, Sa Wang, Jing Cheng, Ming Hu, Minghao Fang, Yue Gao
Institutions: Capital Medical University, Hebei General Hospital, Chinese PLA General Hospital, First Affiliated Hospital of Chinese PLA General Hospital, Second Affiliated Hospital of Zhejiang University, Zhejiang University, Tongji Hospital, Huazhong University of Science and Technology, Wuhan Pulmonary Hospital
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,680
Awards: 基于药物相互作用的参附方毒-效整合分析研究, G8228200946
OpenAlex ID: W3007924766
